Solid Biosciences (SLDB) Return on Capital Employed (2018 - 2026)
Solid Biosciences (SLDB) reported Return on Capital Employed of 66.05% for Q1 2026, down 588.0% on a YoY basis from 13.54% in Q1 2025, and up 19.0% sequentially from 81.55% in Q4 2025.
Solid Biosciences (SLDB) Return on Capital Employed (2018 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 9 years of Return on Capital Employed data on file, last reported at 66.05% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 588.0% year-over-year to 66.05%; the trailing twelve-month figure through Mar 2026 stood at 66.05% (down 588.0% YoY), and the FY2025 full-year result was 101.17%, down 1265.0% from the prior year.
- Return on Capital Employed rose to 66.05% in Q1 2026, from 81.55% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 40.73% in Q1 2022 to a low of 81.55% in Q4 2025.
- A 5-year average of 57.93% and a median of 56.46% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 1998 bps in 2022 and soared 1249 bps in 2024, its largest moves.
- Tracing SLDB's Return on Capital Employed over 5 years: stood at 53.26% in 2022, then decreased by 22 bps to 65.03% in 2023, then declined by 17 bps to 76.32% in 2024, then fell by 7 bps to 81.55% in 2025, then increased by 19 bps to 66.05% in 2026.
- Business Quant data shows SLDB's Return on Capital Employed at 66.05% in Q1 2026, 81.55% in Q4 2025, and 66.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Solid Biosciences | 529.40 Mn | 529.40 Mn | - | -66.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.05% |
| Dec 31, 2025 | -81.55% |
| Sep 30, 2025 | -66.61% |
| Jun 30, 2025 | -52.94% |
| Mar 31, 2025 | -60.17% |
| Dec 31, 2024 | -76.32% |
| Sep 30, 2024 | -56.46% |
| Jun 30, 2024 | -44.43% |
| Mar 31, 2024 | -51.48% |
| Dec 31, 2023 | -65.03% |
| Sep 30, 2023 | -65.15% |
| Jun 30, 2023 | -56.92% |
| Mar 31, 2023 | -50.35% |
| Dec 31, 2022 | -53.26% |
| Sep 30, 2022 | -50.42% |
| Jun 30, 2022 | -46.93% |
| Mar 31, 2022 | -40.73% |
| Dec 31, 2021 | -33.28% |
| Sep 30, 2021 | -31.91% |
| Jun 30, 2021 | -30.88% |